Industry Workshops

Industry Workshop Sponsored by

Advances in High Throughput Paper-Spray Mass Spectrometry (PS-MS) for TDM, Harm Reduction Drug Testing and Clinical Diagnostic Applications

Presented by: Chris Gill, Professor of Chemistry and Co-Director of the Applied Environmental Research Laboratories (AERL), Vancouver Island University

Therapeutic drug monitoring (TDM), Harm Reduction Drug Checking, and Diagnostic Testing represent significant workflow demands and revenue generation for clinical laboratories. Recent fundamental and applied advances made with paper spray mass spectrometry using the Thermo Scientific™ VeriSpray™ source will be presented as a facile and rapid analysis strategies that compare favorably with a validated clinical LC-MS assays, including TDM for clozapine, harm reduction drug checking, and Chronic Kidney Disease detection and monitoring.

Turning False Positive Screening into True Positive Results

Presented by: Melissa Bennett, PhD, MLT, DABCC, Associate Director, Clinical, Alberta Centre for Toxicology, University of Calgary

Dr Bennett will provide an update on her findings from a recent retrospective study revealing how the immunoassay results were positive for benzodiazepine, initially suggesting high false positives from immunoassays when compared results with mass spectrometry. However, upon further investigation identified them as false negatives from novel psychoactive substances (NPS) benzodiazepines undetected by mass spectrometry. With the use of the Thermo Scientific CEDIA high sensitivity kit and our cross-reactivity study, demonstrating its effectiveness with specific NPS compounds (bromazolam, flualprazolam, flubromazolam, flubromazepam and their metabolites).

Industry Workshop Sponsored by

CLAM 2040 Nice Toy or a Game Changer

Presented by: Dr. Frank Streit, Institute of Clinical Chemistry / UMG-Laboratories, University Medical Center Göttingen

The Clinical laboratory automated module CLAM-2040 connected to a SIL-40-HPLC-LC-MS/MS instrument allows a fully automated measurement of hundreds of compounds using several multiparametric LC/-MS/MS methods. A HL7-Interface connected to the LIS reads the barcodes on the sample tubes asking the LIS for request and starts sample preparation, analysis, determination and submits the results automatically. The measurements can easily performed by technicians without special chromatographic or mass spec experience.

An Introduction into the philosophy for using CLAM instrumentation will be given as follows: The CLAM is and will be in future an open user instrumentation for a 24/7 available LCMS-Determination for various applications which can be implemented by users itself. It allows specialists to setup new analytical request and the implementation into clinical routine measurement within a very short time.

Up to now there are several applications note available to be implemented by users or field application specialists from Shimadzu.

In addition there will be also IVDR test KITs available in near future from different vendors, which shows that request for such instrumentation is coming up.

A chrash course how to establish such a test kit on CLAM-2040 may convince to introduce CLAM-2040 in your laboratory.

Starting calibration and qc-samples as well as starting patient sample measurement can be performed with an intuitive user-friendly interface. Quality control sheet can be used for fast qc-results check.

Validation data for antibiotics, antiepileptics, antidepressant, antimycotics, DOACs convince with their accuracy, long term calibration stability and robustness even in random measurement order.

Automated peak identification quantification and validation of results for requested compound or unknown screening allows to run LC-MS/MS methods by non-special LC-MS skilled personel using the HL7-Interface.

Industry Workshop Sponsored by

Therapeutic Drug Monitoring in Psychiatry – Positive impact on patients through lab-clinician collaboration

Presented by: Dr Vincent De Guire, Ph.D, DEPD, CSPQ, Clinical biochemist, Maisonneuve-Rosemont Hospital, Optilab Montreal-CHUM laboratory network, Associated researcher at Maisonneuve-Rosemont Hospital Research Center, Clinical assistant professor at the University of Montreal

Therapeutic drug monitoring (TDM) is pivotal in ensuring patient safety and optimizing treatment outcomes in clinical practice. Fast turnaround times, result consistency and accuracy are critical for a successful implementation to deliver against current clinical needs. This session will highlight the clinical advantages of rapid turnaround times of clozapine measurement, which contributed to safer and more effective management of schizophrenia using the MyCare immunoassay. We will explore updated validation data on the assay’s accuracy and specificity and discuss the impact of inflammation on clozapine concentration. Key strategies for the successful implementation of TDM testing will also be discussed.

Objectives:

1. To illustrate the impact of lab-clinician collaboration on enhancing patient outcomes in schizophrenia.
2. To assess the benefits of faster clozapine measurement turnaround times for improving clinical decisions in schizophrenia.
3. To review strategies for effectively implementing TDM, focusing on the MyCare Clozapine immunoassay’s accuracy, consistency, and specificity.